KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Operations (2016 - 2025)

Historic Cash from Operations for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $999000.0.

  • TherapeuticsMD's Cash from Operations rose 150704.23% to $999000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 15505.65%. This contributed to the annual value of $1.2 million for FY2024, which is 10506.91% up from last year.
  • Latest data reveals that TherapeuticsMD reported Cash from Operations of $999000.0 as of Q3 2025, which was up 150704.23% from $381000.0 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Cash from Operations registered a high of $48.0 million during Q4 2021, and its lowest value of -$38.4 million during Q1 2021.
  • Its 5-year average for Cash from Operations is -$3.5 million, with a median of -$229000.0 in 2024.
  • In the last 5 years, TherapeuticsMD's Cash from Operations plummeted by 13402.57% in 2023 and then skyrocketed by 150704.23% in 2025.
  • Quarter analysis of 5 years shows TherapeuticsMD's Cash from Operations stood at $48.0 million in 2021, then plummeted by 37.01% to $30.2 million in 2022, then plummeted by 116.4% to -$5.0 million in 2023, then surged by 100.34% to $17000.0 in 2024, then soared by 5776.47% to $999000.0 in 2025.
  • Its Cash from Operations was $999000.0 in Q3 2025, compared to $381000.0 in Q2 2025 and $699000.0 in Q1 2025.